MyFinsight
Home
Blog
About
Contact
Download
Download image
Sale and maturities
of available for...
$54,129K
Proceeds from sale of
common stock and...
$705K
Net cash provided by
(used in) investing...
$5,457K
Net cash provided by
financing activities
$657K
Effect of exchange
rates on cash and cash...
$5K
Canceled cashflow
$48,672K
Canceled cashflow
$48K
Net increase
(decrease) in cash and cash...
$403K
Canceled cashflow
$5,716K
Purchase of available for
sale securities
$48,672K
Depreciation and
amortization expense
$2,310K
Accounts receivable
-$1,067K
Stock-based compensation
$670K
Prepaid expenses and
other current assets
-$339K
Change in fair value of
convertible debentures
-$173K
Non-cash lease expense
$122K
Amortization of financing
lease right-of-use...
$51K
Cost of leased
equipment sold to customer
$50K
Disposal of property and
equipment
-$34K
Other long-term
assets
-$16K
Offering expenses on sale
of common stock and...
$28K
Principal payments of
financing lease liability
$20K
Net cash used in
operating activities
-$5,716K
Canceled cashflow
$4,832K
Net loss
-$8,303K
Accrued expenses,
contract liabilities,...
-$1,417K
Accounts payable
-$528K
Accretion of interest on
securities
$194K
Inventory
$106K
Back
Back
Cash Flow
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)
source: myfinsight.com